Develop a country-level business case model for using BPaL regimens for drug-resistent TB treatment
The Health Systems Support Unit has built an economic model for use at country-level to estimate the value-added for changing treatment to the BPaL/BPaLM regimens for appropriate drug resistant TB patient groups. The Global Alliance for TB Drug Development (TB Alliance) has commissioned this work so that it can more effectively advocate for the broader use of the better BPAL treatment regimes.
The model was designed based on a literature review of relevant work in TB programming and other diseases. It captures the minimum essential parameters to be calculate the low-hanging economic fruits offered by these new shorter, cheaper, better regimens.
The model takes into account the cost perspectives of the service providers and of the patient, as far as this is relevant and feasible. The model is robust, flexible and simple to populate with readily available or easy to access data. It provides for capturing, in addition to the drug-resistant TB treatment drugs costs, the ancillary treatment and TB treatment monitoring costs, as far as these are wished and available at country level.
The model was tested in one pilot country (Philippines) for the purpose of proof of concept and further refinement. The generic model is adjusted for specific country contexts, while allowing broadest generalizability to other contexts and for comparison across the foreseen broad application in numerous (10-15) priority countries.
Results of the tool will be used by TB Alliance to illustrate the savings potential of switching to BPaL treatment regimes for drug-resistant TB patients alongside the better treatment outcomes these bring with them.